Inhalation
PreclinicalSmall molecule
Inhalation is one of 35 small molecule programs targeting Tics. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
114 competitors in Tics
#DrugCompanyPhaseTrials
1Sodium Valproate
AstraZenecaPhase 3
Priftin
SanofiPhase 2
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Duvyzat
ItalfarmacoPhase 2
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 2
CAB LA
GSKPhase 2
Abexinostat
XXynomic Pharmaceuticals, Inc.
Phase 2
Cocaine Hydrochloride
NNoden Pharma
Phase 3
Anaprazole
SSihuan Pharmaceutical Holdings Group Ltd.
Phase 3
Dostinex
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inhalation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPari Pharma GmbH